HOME >> BIOLOGY >> NEWS
Chromosomal tests can determine brain tumor therapy, outcomes, Jefferson oncologists find

Philadelphia- A trial involving two types of rare, malignant but treatable brain tumors shows that missing portions of two chromosomes can predict which patients will likely do better with therapy. The results, says senior author Walter J. Curran Jr., M.D., professor and chair of radiation oncology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, represents a paradigm shift in treating such tumors, known as gliomas.

Reporting last week in the Journal of Clinical Oncology, Dr. Curran and a team of American and Canadian researchers, in conjunction with the Philadelphia-based Radiation Therapy Oncology Group (RTOG), a federally-supported clinical trials organization, found that among 289 patients with either anaplastic oligodendroglioma or anaplastic oligoastrocytoma receiving either a combination of three chemotherapy drugs with radiation or radiation alone, those whose tumors had deletions in chromosome locations 1p and 19q tended to live nearly two and a half times longer than those patients without the missing chromosome portions. The "median survival time" of patients with the deletions was greater than seven years, meaning that one-half lived at least that long. For those with tumors lacking such deletions, one-half lived at least 2.8 years.

"Leukemias used to be the only cancers where chromosomal deletions were part of the treatment decision-making process," says Dr. Curran, who is also clinical director of the Kimmel Cancer Center at Jefferson. "Now, testing for such deletions in tumors should become mandatory for at least these types of gliomas."

In the study, 147 patients received the chemotherapy and radiation, while 142 were given only radiation. These rare, malignant tumors can be effectively treated, though seldom "cured" with surgery and radiation. One controversy, explains Dr. Curran, was whether or not adding chemotherapy early in the treatment will help individuals live longer.
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
30-Jun-2006


Page: 1 2 3

Related biology news :

1. Chromosomal microarray analysis proves accurate
2. Chromosomal abnormalities in sperm higher after vasectomy reversal
3. Nearly 90 percent of babies receive recommended newborn screening tests
4. Study to probe how healthy younger adults make use of genetic tests
5. Laser goes tubing for faster body-fluid tests
6. Blood tests may be possible for mental health conditions
7. Embryo tests give parents the choice
8. Chemical tests of cell growth enter third dimension
9. Study shows prenatal diagnostic tests have low risk of miscarriage
10. Apes -- not monkeys -- ace IQ tests
11. Stress imaging tests predict prognosis of heart disease in obese persons

Post Your Comments:
(Date:6/15/2015)... , June 16, 2015 ... Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies ... Forecast to 2020" published by MarketsandMarkets, The Natural Language ... at a CAGR of 18.4% for the forecast period ... and   46 F igures spread   through ...
(Date:6/10/2015)... 2015 According to a ... Technology (Ultrasound, TOF, Structured Light, Stereo Vision), Type(Image, ... and by Geography - Trends & Forecast to ... is expected to reach $3,319.71 Million by 2020, ... and 2020. Browse 71 market data ...
(Date:6/5/2015)... 5, 2015  Intrexon Corporation ("Intrexon") (NYSE: XON ... it has determined the final distribution ratio relating to ... shares of ZIOPHARM Oncology, Inc. ("ZIOPHARM") (NASDAQ: ZIOP ... the distribution date, as a pro rata dividend on ... purchase shares of Intrexon common stock ("Warrants"), outstanding on ...
Breaking Biology News(10 mins):Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 53D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4
(Date:6/29/2015)... ... 2015 , ... The global microfluidics market is expected to ... to 2020). The market is mainly driven by the rising geriatric population, growing ... lack of adequate healthcare and research infrastructure in emerging markets, dearth of skilled ...
(Date:6/29/2015)... 2015  Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical ... molecule and cell therapy treatments for central nervous system ... listing on the NASDAQ Capital Market under the symbol ... on the NYSE MKT until the market close on ... is expected to commence on July 13, 2015. ...
(Date:6/29/2015)... , June 29, 2015   For the seventh year ... to assess their overall digital maturity called the ... these companies are not maturing fast enough. While it,s ... in numerous ways overall and customers are increasingly "digital ... of digital customer engagement.  ...
(Date:6/26/2015)... VANCOUVER , June 26, 2015 /PRNewswire/ - iCo ... ICOTF), today announced that all nominees listed in ... as directors at its 2015 Annual Meeting of ... a vote by ballot, the following 5 nominees ... iCo Therapeutics to serve until the Company,s next ...
Breaking Biology Technology:Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
Cached News: